Efficacy of ileus tube combined with meglumine diatrizoate in treating postoperative inflammatory bowel obstruction after surgery

Table 1 Comparative analyses for clinical efficacy among all cohorts [cases (%)]

Cohort	Cure	Effective	Ineffective	Total effective rate
Cohort A (n=20)	11 (55.00)	8 (40.00)	1 (5.00)	19 (95.00)a
Cohort B (n=20)	9 (45.00)	7 (35.00)	4 (20.00)	16 (80.00)
Cohort C (n=20)	7 (35.00)	5 (25.00)	8 (40.00)	12 (60.00)
χ2 values				7.267
P value				0.026

^aIndicated P < 0.05 compared to cohort C.

There is no significant difference between group A and group B.

Table 2 Comparative analyses for prognosis among all cohorts (x ± s)

Cohort	Time of first exhaust/defecation (d)	Length of hospital stay (d)	Gastrointestinal decompression time (d)	Relief time of abdominal pain (d)	Relief time of abdominal distention (d)
Cohort A (n = 20)	7.85 ± 1.53a,b	15.30 ± 1.95c	11.30 ± 1.84a,b	2.05 ± 0.51a,b	5.55 ± 1.79a,b
Cohort B (n = 20)	10.75 ± 2.86c	17.10 ± 2.57c	14.40 ± 2.74c	3.00 ± 1.12	3.85 ± 1.09
Cohort C (n = 20)	13.05 ± 1.90	20.25 ± 2.53	16.35 ± 1.60	3.60 ± 1.35	3.55 ± 1.10
F value	28.749	22.381	28.933	10.923	12.458
P value	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

^aIndicated P < 0.05 when compared to cohort B.

^bIndicated P < 0.05 when compared to cohort C.

Table 3 Comparative analyses for inflammatory factors levels pre-/post-therapy in all cohorts (x ± s)

Cohort	CRP (mg/L)		TNF-α (ng/L)		IL-6 (ng/L)		MCP-1 (ng/L)
	Pre-therapy	Post-therapy	Pre-therapy	Post-therapy	Pre-therapy	Post-therapy	Pre- therapy	Post-therapy
Cohort A (n = 20)	32.84 ± 3.90	17.14 ± 2.27a,b,c	10.11 ± 1.74	2.62 ± 0.83a,b,c	34.92 ± 2.31	15.27 ± 1.15a,b,c	213.33 ± 14.91	122.91 ± 19.00a,b,c
Cohort B (n = 20)	34.40 ± 4.67	19.99 ± 3.51a,c	11.03 ± 1.99	3.79 ± 1.06a,c	35.59 ± 1.59	18.88 ± 1.58a,c	215.24 ± 19.15	150.74 ± 19.76a,c
Cohort C (n = 20)	32.27 ± 2.78	25.16 ± 2.41a	10.80 ± 2.06	5.35 ± 0.95a	34.92 ± 3.09	23.43 ± 2.26a	211.07 ± 16.46	167.83 ± 15.10a
F value	1.636	42.566	1.227	41.469	0.526	112.506	0.303	31.482
P value	0.204	< 0.001	0.301	< 0.001	0.594	< 0.001	0.740	< 0.001

^aIndicated P < 0.05 when compared with the same cohort pre-therapy.

^bIndicated P < 0.05 when compared with cohort B.

^cIndicated P < 0.05 when compared with cohort C.

CRP: C-reactive protein; TNF-α: Tumor necrosis factor-alpha; IL-6: Interleukin-6; MCP-1: Monocyte chemoattractant protein-1.

Table 4 Comparative analyses for nutritional status of all cohorts pre- and post-therapy (x ± s)

Cohort	Serum albumin (g/L)		Serum transferrin (g/L)
	Pre-therapy	Post-therapy	Pre-therapy	Post-therapy
Cohort A (n = 20)	43.46 ± 3.33	49.88 ± 3.60a,c	2.24 ± 0.53	3.55 ± 0.42a,b,c
Cohort B (n = 20)	42.79 ± 4.36	47.90 ± 3.90a	2.02 ± 0.55	3.16 ± 0.23a
Cohort C (n = 20)	43.58 ± 2.14	46.68 ± 2.41a	2.27 ± 0.49	2.13 ± 0.51a
F value	0.306	4.596	1.377	7.000
P value	0.737	0.014	0.261	0.002

^aIndicated P < 0.05 when compared with the same cohort pre-therapy.

^bIndicated P < 0.05 when compared with cohort B.

^cIndicated P < 0.05 when compared with cohort C.

Table 5 Comparative analyses for adverse event occurrence among all cohorts [cases (%)]

Cohort	Anorexia	Vomiting	Tube obstruction	Rash	The total incidence of adverse reactions
Cohort A (n = 20)	1 (5.00)	4 (20.00)	0 (0.00)	0 (0.00)	5 (25.00)
Cohort B (n = 20)	1 (5.00)	3 (15.00)	1 (5.00)	1 (5.00)	6 (30.00)
Cohort C (n = 20)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
Fisher’s exact probability value					0.029